Objectives
To provide BD&L support by assessing the current and future market landscape and the resulting pricing and access potential for PRODUCT X in Leber hereditary optic neuropathy (LHON).
Scope
Methodology
Conduct in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practice and price thresholds for LHON, and understand likely payer restrictions as a function of price for a gene therapy.
Deliverables
- Landscape assessment and analogue assessment across key markets
- Payer & KOL moderator guides and research stimuli
- Interim research findings summary
- Detailed final research findings summary
- Strategic business development and licensing (BD&L) recommendations and differentiation opportunities
Illustrative Outputs
Impact
CBP informed a BD&L strategy in LHON with a detailed P&MA opportunity for each in-scope market.